HOME >> MEDICINE >> NEWS
Results of NUVANCE (IL-4 receptor) in Phase I/II study in asthma patients featured at AAAAI Late-Breaker Abstract and Asthma Therapy Sessions

SAN DIEGO - The results of a Phase I/II study of NUVANCE™ (IL-4 receptor) in adult patients with moderate asthma will be featured at the Late-Breaker Abstract Session at the American Academy of Allergy, Asthma and Immunology's (AAAAI) 56th Annual Meeting (March 3-8 in San Diego, California).

WHEN: Saturday, March 4, 2000, 3:00 pm

WHERE: Late Breaker: New Therapies Mini-symposium, Room 8, Upper Level of the San Diego Convention Center.

WHO: Dr. Jonathan Corren, MD, Medical Director, Allergy Research Foundation, and lead investigator will present the results of Phase I/II study of NUVANCE™ in adult patients with moderate asthma. Dr. Corren is affiliated with the University of California, Los Angeles.

A presentation entitled, "Cytokines and Cytokine Therapy for Allergic Diseases: Which One is the Most Critical? Il-4 and IL-4 Receptor Antagonists in Allergic Disease," will also be featured at the AAAAI Annual Meeting.

WHEN: Monday, March 6, 2000, 8:45 am - 10:45 am

WHERE: Asthma Therapy Symposium, Marina Ballroom G, Level 3, South Tower, Marriott.

WHO: Dr. Jan Agosti, Medical Director, Immunex Corp., will present scientific evidence and clinical data demonstrating the potential of IL-4 inhibition to improve lung function and control the symptoms of people with asthma.

Interleukin-4 (IL-4) is a naturally occurring cytokine, or immune system protein, that has been commonly associated with the development of asthma and allergies. It binds to specific IL-4 receptors (IL-4R) on the surface of cells in the body or to naturally occurring soluble receptors that circulate throughout the body. Increased levels of IL-4 appear to be related to increased severity of asthma that results in difficulty in breathing. Immunex scientists used recombinant DNA technology to produce a soluble IL-4 receptor, a molecule the company names NUVANCE. When IL-4 binds with NUVANCE instead of cell-surface IL-4R, the effects of IL-4 may be block
'"/>

Contact: Tim Warner
warnert@immunex.com
206-470-4193
Immunex Corporation
1-Mar-2000


Page: 1 2

Related medicine news :

1. Heart transplant survival: Results may be key to rejection prevention, detection, treatment
2. Docetaxel versus paclitaxel in breast cancer Results of worlds first head to head trial
3. Results from first clinical trial using GVG to treat addiction
4. Results of first chronic treatment study with oral EXANTA(TM) (ximelagatran)
5. Media Advisory-- Results of California autism epidemiology study to be unveiled
6. Results of Yale study confirm aspirin helpful in preventing a first heart attack
7. Yale study shows way to re-stimulate brain cell growth: Results could boost understanding of Alzheimers, other brain disorders
8. Results of NUVANCE phase I/II asthma trial presented
9. ILEX Oncology & LeukoSite report results from pivotal Phase II CAMPATH (R) trial; Results suggest new hope for refractory chronic lymphocytic leukemia
10. UI Study Yields Encouraging Results For New Breast Cancer Treatment
11. Ph.D. Degree Research Results In Patent For Low-Cost Pharmaceutical Filters Made From Seafood Waste

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/2/2018)... (PRWEB) , ... September 01, ... ... Mammography is proud to add HydraFacial MD® Elite to its leading menu ... uses patented, vortex-suction technology and an infusion of clinically-proven ingredients to dramatically ...
(Date:9/1/2018)... ... August 31, 2018 , ... SignatureCare Emergency Center is ... for the Fall semester to a deserving student. Get your applications in now as ... was awarded to Hanna Wu who is a medical student at Texas Southern University. ...
(Date:8/31/2018)... , ... August 31, 2018 , ... ... | 2018" list. , This list includes independent community hospitals as well as ... others care for small communities outside of large cities. The hospitals continue to ...
(Date:8/31/2018)... ... 31, 2018 , ... The social impact documentary feature film on homelessness, OFF ... NIH-funded researcher Luciana Lagana, aka Dr. Luciana, has been faring well at film ... Film Festival, IndieFEST Film Awards, Shawna Shea Memorial Film Festival, and Top Indie Film ...
(Date:8/31/2018)... ... August 31, 2018 , ... Rudina Thanasi, a scientifically validated ... energy treated nutraceutical to improve overall immunity and to combat inflammatory and autoimmune ... well as, inflammation. The following data was reported:,     Over ...
Breaking Medicine News(10 mins):
(Date:9/15/2018)... Calif. (PRWEB) , ... September ... ... phage display for molecular evolution incorporate deep sequencing to enable greater library ... construction and biophysical follow-up of potential hits remain. , Multiplexed phage display ...
(Date:9/13/2018)... (PRWEB) , ... September 13, 2018 , ... The ultimate ... Located at 31-57 31st St., the new arrival is called Form50 Fitness . ... by Sebastien Lagree called The Megaformer™ - a hybrid Pilates reformer with pulleys, weights, ...
(Date:9/13/2018)... ... September 13, 2018 , ... NCPDP announced today that its ... correct implementation of the NCPDP SCRIPT Standard Version 2017071 ahead of the January ... identified by the industry as vital enhancements in improving patient safety, clinical decision-making, ...
Breaking Medicine Technology:
Cached News: